Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands

Expert Opinion on Investigational Drugs

Volumn 23, Issue 8, 2014, Pages 1123-1140

  Davis, Mellar P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Arachidonoyl; Bifunctional; Cannabinoid; Endocannabinoid; Enzyme; Ethanolamine; Orphan cannabinoid receptor; Pain; Peroxisome proliferator activated receptor; Receptor

Indexed keywords

AJULEMIC ACID; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; FLUTAMIDE; G PROTEIN COUPLED RECEPTOR; HYDROLASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VANILLOID RECEPTOR ANTAGONIST; ANALGESIC AGENT; CANNABINOID RECEPTOR AGONIST; LIGAND;

ADVERSE OUTCOME; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; ARTHRITIS; BIOLOGICAL ACTIVITY; CALCIUM CONDUCTANCE; CLINICAL TRIAL (TOPIC); COLITIS; DRUG INDUSTRY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HYPERALGESIA; HYPOTENSION; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY PAIN; INVERSE AGONISM; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PAIN PARAMETERS; PAIN THRESHOLD; PAW EDEMA; PHARMACOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SKIN DEFECT; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION; UPREGULATION; WOUND; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; METABOLISM; PAIN; PATHOPHYSIOLOGY;

ANALGESICS; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; DRUG DESIGN; ENDOCANNABINOIDS; HUMANS; LIGANDS; PAIN; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84904340615     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.918603     Document Type: Review

References (202)

1. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-Tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29(9): 2068-79
2. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioidtreated cancer patients with poorlycontrolled chronic pain: A randomized, placebo-controlled, graded-dose trial. J Pain 2012;13(5): 438-49
3. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013;260(4): 984-97
4. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, doubleblind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39(2): 167-79
5. Klumpers LE, Beumer TL, van Hasselt JG, et al. Novel delta(9)- Tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012;74(1): 42-53
6. Clermont-Gnamien S, Atlani S, Attal N, et al. The therapeutic use of D9-Tetrahydrocannabinol (dronabinol) in refractory neuropathic pain. Presse Med 2002;31(39 Pt 1): 1840-5
7. Turcotte D, Le Dorze JA, Esfahani F, et al. Examining the roles of cannabinoids in pain and other therapeutic indications: A review. Expert Opin Pharmacother 2010;11(1): 17-31
8. Attal N, Brasseur L, Guirimand D, et al. Are oral cannabinoids safe and effective in refractory neuropathic paiñ Eur J Pain 2004;8(2): 173-7
9. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-Term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 2013;46(2): 207-18
10. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3): 210-20
11. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-Analysis of cannabis treatment for chronic pain. Pain Med 2009;10(8): 1353-68
12. Iskedjian M, Bereza B, Gordon A, et al. Meta-Analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007;23(1): 17-24
13. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia 2004;59(5): 440-52
14. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampaldependent memory impairment. J Psychopharmacol 2013;27(1): 19-27
15. Kalliomaki J, Annas P, Huizar K, et al. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol 2013;40(3): 212-18
16. Maione S, Costa B, Piscitelli F, et al. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as dual-Target analgesics. Pharmacol Res 2013;76: 98-105
17. Guindon J, Lai Y, Takacs SM, et al. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-Acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res Jan;2013;67(1): 94-109
18. Solorzano C, Zhu C, Battista N, et al. Selective N-Acylethanolamine- hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci USA 2009;106(49): 20966-71
19. Croci T, Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br J Pharmacol 2007;150(5): 559-66
20. Piomelli D. More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 2014;76(Pt B): 228-34
21. Iring A, Ruisanchez E, Leszl-Ishiguro M, et al. Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One 2013;8(1): E53390
22. Desroches J, Charron S, Bouchard JF, Beaulieu P. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB1 and CB2 receptors. Neuropharmacology 2014;77: 441-52
23. Izzo AA, Sharkey KA. Cannabinoids and the gut: New developments and emerging concepts. Pharmacol Ther 2010;126(1): 21-38
24. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009;8(6): 403-21
25. Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.Br J Pharmacol 2013;168(3): 554-75
26. Vasileiou I, Fotopoulou G, Matzourani M, et al. Evidence for the involvement of cannabinoid receptors'polymorphisms in the pathophysiology of human diseases. Expert Opin Ther Targets 2013;17(4): 363-77
27. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152(7): 1092-101
28. Sawzdargo M, Nguyen T, Lee DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999;64(2): 193-8
29. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics 2009;6(4): 713-37
30. Hoehe MR, Caenazzo L, Martinez MM, et al. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 1991;3(9): 880-5
31. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279(Pt 1): 129-34
32. Beltramo M, Bernardini N, Bertorelli R, et al. CB2 receptor-mediated antihyperalgesia: Possible direct involvement of neural mechanisms. Eur J Neurosci 2006;23(6): 1530-8
33. Sagar DR, Jhaveri M, Chapman V. Targeting the cannabinoid system to produce analgesia. Curr Top Behav Neurosci 2009;1: 275-87
34. Straiker A, Wager-Miller J, Hutchens J, Mackie K. Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. Br J Pharmacol 2012;165(8): 2660-71
35. Laprairie RB, Kelly ME, Denovan-Wright EM. The dynamic nature of type 1 cannabinoid receptor (CB(1)) gene transcription. Br J Pharmacol 2012;167(8): 1583-95
36. Uriguen L, Garcia-Fuster MJ, Callado LF, et al. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment. Psychopharmacology (Berl) 2009;206(2): 313-24
37. Seely KA, Brents LK, Franks LN, et al. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology 2012;63(5): 905-15
38. Tsumura M, Sobhan U, Muramatsu T, et al. TRPV1-mediated calcium signal couples with cannabinoid receptors and sodium-calcium exchangers in rat odontoblasts. Cell Calcium 2012;52(2): 124-36
39. Przybyla JA, Watts VJ. Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 2010;332(3): 710-19
40. Rahn EJ, Zvonok AM, Thakur GA, et al. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008;327(2): 584-91
41. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152(5): 765-77
42. den Boon FS, Chameau P, Schaafsma-Zhao Q, et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci USA 2012;109(9): 3534-9
43. Callen L, Moreno E, Barroso-Chinea P, et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 2012;287(25): 20851-65
44. Pertwee RG, Howlett AC, Abood ME, et al. International Union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacol Rev 2010;62(4): 588-631
45. McHugh D, Page J, Dunn E, Bradshaw HB. Delta(9)-Tetrahydrocannabinol and N-Arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 2012;165(8): 2414-24
46. Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett 2011;500(1): 72-6
47. Breen C, Brownjohn PW, Ashton JC. The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. Neurosci Lett 2012;508(2): 119-22
48. Hollinshead SP, Tidwell MW, Palmer J, et al. Selective cannabinoid receptor type 2 (CB2) agonists: Optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. J Med Chem 2013;56(14): 5722-33
49. Han S, Thatte J, Buzard DJ, Jones RM. Therapeutic utility of cannabinoid receptor type 2 (CB) selective agonists. J Med Chem 2013;56(21): 8224-56
50. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001;410(6828): 588-92
51. Yoshida T, Fukaya M, Uchigashima M, et al. Localization of diacylglycerol lipasealpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-Arachidonoylglycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 2006;26(18): 4740-51
52. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006;45(5): 405-46
53. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-Acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006;45(15): 4720-6
54. Liu J, Wang L, Harvey-White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008;54(1): 1-7
55. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-Arachidonoylglycerol. Chem Biol 2007;14(12): 1347-56
56. Nyilas R, Gregg LC, Mackie K, et al. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci 2009;29(10): 1964-78
57. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008;14(9): 923-30
58. Sugiura T, Waku K. 2-Arachidonoylglycerol: A possible multifunctional lipid mediator in the nervous and immune systems. Ann N Y Acad Sci 2000;905: 344-6
59. Gonsiorek W, Lunn C, Fan X, et al. Endocannabinoid 2-Arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol Pharmacol 2000;57(5): 1045-50
60. LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferatoractivated receptor-Alpha. J Pharmacol Exp Ther 2006;319(3): 1051-61
61. LoVerme J, La Rana G, Russo R, et al. The search for the palmitoylethanolamide receptor. Life Sci 2005;77(14): 1685-98
62. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010;17(14): 1360-81
63. Higgins A, Yuan S, Wang Y, Burrell BD. Differential modulation of nociceptive versus non-nociceptive synapses by endocannabinoids. Mol Pain 2013;9: 26
64. Haj-Dahmane S, Shen RY. Endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through the activation of presynaptic CB1 receptors. J Pharmacol Exp Ther 2009;331(1): 186-96
65. Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006;11(3): 274-84
66. Desroches J, Guindon J, Lambert C, Beaulieu P. Modulation of the antinociceptive effects of 2-Arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 2008;155(6): 913-24
67. Bacci A, Huguenard JR, Prince DA. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 2004;431(7006): 312-16
68. Heifets BD, Castillo PE. Endocannabinoid signaling and longterm synaptic plasticity. Ann Rev Physiol 2009;71: 283-306
69. Sagar DR, Gaw AG, Okine BN, et al. Dynamic regulation of the endocannabinoid system: Implications for analgesia. Mol Pain 2009;5: 59
70. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for Npalmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 2001;276(38): 35552-7
71. Chicca A, Marazzi J, Nicolussi S, Gertsch J. Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem 2012;287(41): 34660-82
72. Starowicz K, Przewlocka B. Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci 2012;367(1607): 3286-99
73. Fioravanti B, De Felice M, Stucky CL, et al. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: Antinociceptive actions of CB1 inverse agonists. J Neurosci 2008;28(45): 11593-602
74. Krishtal O, Lozovaya N, Fedorenko A, et al. The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. Pflugers Arch 2006;453(3): 353-60
75. Hu SS, Bradshaw HB, Chen JS, et al. Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-Arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 2008;153(7): 1538-49
76. Piscitelli F, Di Marzo V. Redundancyof endocannabinoid inactivation: New challenges and opportunities for pain control. ACS Chem Neurosci 2012;3(5): 356-63
77. Fowler CJ. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 2007;152(5): 594-601
78. Guay J, Bateman K, Gordon R, et al. Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 2004;279(23): 24866-72
79. Nevalainen T. Recent development of CB2 selective and peripheral CB1/ CB2 cannabinoid receptor ligands. Curr Med Chem 2013;21(2): 187-203
80. Yu XH, Cao CQ, Martino G, et al. A peripherally restricted cannabinoid receptor agonist produces robust antinociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 2010;151(2): 337-44
81. Rahn EJ, Thakur GA, Wood JA, et al. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects. Pharmacol Biochem Behav 2011;98(4): 493-502
82. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156(3): 397-411
83. Kelly S, Jhaveri MD, Sagar DR, et al. Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci 2003;18(8): 2239-43
84. Akopian AN, Ruparel NB, Jeske NA, et al. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 2009;30(2): 79-84
85. Katsuyama S, Mizoguchi H, Kuwahata H, et al. Involvement of peripheral cannabinoid and opioid receptors in beta-caryophyllene-induced antinociception. Eur J Pain 2013;17(5): 664-75
86. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005;48(8): 1164-71
87. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. JAMA 2003;290(13): 1757-62
88. Ambrosio AL, Dias SM, Polikarpov I, et al. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-Activated receptor gamma. J Biol Chem 2007;282(25): 18625-33
89. Cui JH, Kim WM, Lee HG, et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55, 212-2 in a rat bone tumor pain model. Neurosci Lett 2011;493(3): 67-71
90. Cui JH, Ju J, Yoon MH. Pharmacology of cannabinoid receptor agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain. Pharmacology 2013;92(3-4): 150-7
91. Wilkerson JL, Gentry KR, Dengler EC, et al. Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal antiinflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav 2012;2(2): 155-77
92. Potenzieri C, Harding-Rose C, Simone DA. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008;1215: 69-75
93. Uhelski ML, Cain DM, Harding-Rose C, Simone DA. The nonselective cannabinoid receptor agonist WIN 55, 212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain. Neuroscience 2013;247: 84-94
94. Gu X, Mei F, Liu Y, et al. Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-Aspartic acid. Anesth Analg 2011;113(2): 405-11
95. Khasabova IA, Chandiramani A, Harding-Rose C, et al. Increasing 2-Arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 2011;64(1): 60-7
96. Khasabova IA, Gielissen J, Chandiramani A, et al. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 2011;22(5-6): 607-16
97. Dogrul A, Gul H, Akar A, et al. Topical cannabinoid antinociception: Synergy with spinal sites. Pain 2003;105(1-2): 11-16
98. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003;52(6): 238-45
99. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003;102(3): 283-8
100. Wallace JL, Flannigan KL, McKnight W, et al. Pro-resolution, protective and antinociceptive effects of a cannabis extract in the rat gastrointestinal tract. J Physiol Pharmacol 2013;64(2): 167-75
101. Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013;85(9): 1306-16
102. Esposito G, Capoccia E, Turco F, et al. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-Alpha activation. Gut 2013. [Epub ahead of print]
103. Matos I, Bento AF, Marcon R, et al. Preventive and therapeutic oral administration of the pentacyclic triterpene alpha, beta-Amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. Mol Immunol 2013;54(3-4): 482-92
104. Jamontt JM, Molleman A, Pertwee RG, Parsons ME. The effects of Deltatetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 2010;160(3): 712-23
105. Gadotti VM, You H, Petrov RR, et al. Analgesic effect of a mixed T-Type channel inhibitor/CB2 receptor agonist. Mol Pain 2013;9: 32
106. Riether D. Selective cannabinoid receptor 2 modulators: A patent review 2009-present. Expert Opin Ther Pat 2012;22(5): 495-510
107. Naderi N, Majidi M, Mousavi Z, et al. The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-beta expression in rats. Neurochem Res 2012;37(4): 778-85
108. Baillie GL, Horswill JG, Anavi-Goffer S, et al. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 2013;83(2): 322-38
109. Ahn KH, Mahmoud MM, Kendall DA. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi proteinindependent ERK1/2 kinase activation. J Biol Chem 2012;287(15): 12070-82
110. Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 2005;67(6): 2016-24
111. Tumati S, Largent-Milnes TM, Keresztes A, et al. Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-Administration of a selective cannabinoid receptor type-2 agonist. J Neuroimmunol 2012;244(1-2): 23-31
112. Ahn DK, Choi HS, Yeo SP, et al. Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain 2007;132(1-2): 23-32
113. Ramesh D, Ross GR, Schlosburg JE, et al. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 2011;339(1): 173-85
114. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012;367(1607): 3353-63
115. Bolognini D, Costa B, Maione S, et al. The plant cannabinoid Delta9-Tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 2010;160(3): 677-87
116. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-Tetrahydrocannabinol, cannabidiol and delta9- Tetrahydrocannabivarin. Br J Pharmacol 2008;153(2): 199-215
117. Racz I, Nadal X, Alferink J, et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 2008;28(46): 12125-35
118. Bishay P, Schmidt H, Marian C, et al. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One 2010;5(5): E10628
119. Spradley JM, Guindon J, Hohmann AG. Inhibitors of monoacylglycerol lipase, fatty-Acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 2010;62(3): 249-58
120. Kinsey SG, Naidu PS, Cravatt BF, et al. Fatty acid amide hydrolase blockade attenuates the development of collageninduced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav 2011;99(4): 718-25
121. Booker L, Kinsey SG, Abdullah RA, et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol 2012;165(8): 2485-96
122. Caprioli A, Coccurello R, Rapino C, et al. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J Pharmacol Exp Ther 2012;342(1): 188-95
123. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 2014;171(6): 1392-407
124. Guindon J, Guijarro A, Piomelli D, Hohmann AG. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 2011;163(7): 1464-78
125. Long JZ, Li W, Booker L, et al. Selective blockade of 2-Arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009;5(1): 37-44
126. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-Allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 2010;11(12): 1420-8
127. Kinsey SG, Long JZ, O'Neal ST, et al. Blockade of endocannabinoid- degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009;330(3): 902-10
128. Maione S, Bisogno T, de Novellis V, et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006;316(3): 969-82
129. Kinsey SG, Nomura DK, O'Neal ST, et al. Inhibition of monoacylglycerol lipase attenuates nonsteroidal antiinflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 2011;338(3): 795-802
130. Starowicz K, Di Marzo V. Non-psychotropic analgesic drugs from the endocannabinoid system: Magic bullet or multiple-Target strategieš Eur J Pharmacol 2013;716(1-3): 41-53
131. Chanda PK, Gao Y, Mark L, et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 2010;78(6): 996-1003
132. Starowicz K, Makuch W, Osikowicz M, et al. Spinal anandamide produces analgesia in neuropathic rats: Possible CB (1)-And TRPV1-mediated mechanisms. Neuropharmacology 2012;62(4): 1746-55
133. Huggins JP, Smart TS, Langman S, et al. An efficient randomised, placebocontrolled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012;153(9): 1837-46
134. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 2010;11(1): 51-62
135. Di Marzo V. Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all. Pain 2012;153(9): 1785-6
136. Taylor BK. N-Acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia. Pain 2013;154(3): 326-7
137. Costa B, Trovato AE, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007;556(1-3): 75-83
138. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARalpha agonist palmitoylethanolamide. Br J Pharmacol 2013;168(6): 1430-44
139. Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001;358(Pt 1): 249-55
140. Di Marzo V, Bisogno T, De Petrocellis L. Anandamide: Some like it hot. Trends Pharmacol Sci 2001;22(7): 346-9
141. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008;139(1): 225-36
142. Sasso O, Moreno-Sanz G, Martucci C, et al. Antinociceptive effects of the Nacylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain 2013;154(3): 350-60
143. Kozela E, Lev N, Kaushansky N, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol 2011;163(7): 1507-19
144. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30(10): 515-27
145. Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007;150(5): 613-23
146. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163(7): 1479-94
147. Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004;369(3): 294-9
148. Rock EM, Bolognini D, Limebeer CL, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012;165(8): 2620-34
149. Maione S, Piscitelli F, Gatta L, et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 2011;162(3): 584-96
150. Espejo-Porras F, Fernandez-Ruiz J, Pertwee RG, et al. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology 2013;75: 155-63
151. El-Remessy AB, Tang Y, Zhu G, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: Critical role of p38 MAPK activation. Mol Vis 2008;14: 2190-203
152. Varvel SA, Wiley JL, Yang R, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 2006;186(2): 226-34
153. Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 2011;89(3): 400-7
154. Ward SJ, McAllister SD, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 2014;Feb;171(3): 636-45
155. Ramer R, Heinemann K, Merkord J, et al. COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 2013;12(1): 69-82
156. Franklin A, Stella N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur J Pharmacol 2003;474(2-3): 195-8
157. McHugh D, Hu SS, Rimmerman N, et al. N-Arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 2010;11: 44
158. Beggs S, Salter MW. The known knowns of microglia-neuronal signalling in neuropathic pain. Neurosci Lett 2013;557(Pt A): 37-42
159. Schicho R, Bashashati M, Bawa M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 2011;17(8): 1651-64
160. Ashton JC. The atypical cannabinoid O-1602: Targets, actions, and the central nervous system. Cent Nerv Syst Agents Med Chem 2012;12(3): 233-9
161. Zhao P, Abood ME. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci 2013;92(8-9): 453-7
162. Balenga NA, Aflaki E, Kargl J, et al. GPR55 regulates cannabinoid 2 receptormediated responses in human neutrophils. Cell Res 2011;21(10): 1452-69
163. Lauckner JE, Jensen JB, Chen HY, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008;105(7): 2699-704
164. Oka S, Nakajima K, Yamashita A, et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007;362(4): 928-34
165. McHugh D. GPR18 in microglia: Implications for the CNS and endocannabinoid system signalling. Br J Pharmacol 2012;167(8): 1575-82
166. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA 2003;100(8): 4903-8
167. McHugh D, Roskowski D, Xie S, Bradshaw HB. Delta(9)-THC and Narachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: Implications for signaling at GPR18. Front Pharmacol 2014;4: 162
168. Costa B. Rimonabant: More than an anti-obesity drug? Br J Pharmacol 2007;150(5): 535-7
169. Wang Q, Perrard XD, Perrard JL, et al. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity 2011;19(3): 505-13
170. Croci T, Landi M, Galzin AM, Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factoralpha in the gut and systemic antiinflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 2003;140(1): 115-22
171. Detloff MR, Fisher LC, McGaughy V, et al. Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp Neurol 2008;212(2): 337-47
172. Costa B, Trovato AE, Colleoni M, et al. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005;116(1-2): 52-61
173. Heimann AS, Gomes I, Dale CS, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 2007;104(51): 20588-93
174. Hama A, Sagen J. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain. Brain Res 2011;1412: 44-54
175. Fichna J, Sibaev A, Salaga M, et al. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol Motil 2013;25(8): E550-9
176. Murineddu G, Asproni B, Pinna GA. A survey of recent patents on CB2 agonists in the management of pain. Recent Pat CNS Drug Discov 2012;7(1): 4-24
177. Ostenfeld T, Price J, Albanese M, et al. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain 2011;27(8): 668-76
178. Finn DP, Beckett SR, Roe CH, et al. Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 2004;19(3): 678-86
179. Hewitt DJ, Ho TW, Galer B, et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 2011;152(3): 514-21
180. Ikeda H, Ikegami M, Kai M, et al. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice. Neuroscience 2013;250: 446-54
181. Burston JJ, Sagar DR, Shao P, et al. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 2013;8(11): E80440
182. Cox ML, Haller VL, Welch SP. The antinociceptive effect of Delta9-Tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur J Pharmacol 2007;570(1-3): 50-6
183. Atwood BK, Straiker A, Mackie K. CB (2) cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. Neuropharmacology 2012;63(4): 514-23
184. Yao BB, Hsieh G, Daza AV, et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2, 2, 3, 3- Tetramethylcyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4, 5-dimethyl-3H-Thiazol-(2Z)-ylidene]-Amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 2009;328(1): 141-51
185. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA. Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain 2009;5: 25
186. Wilkerson JL, Gentry KR, Dengler EC, et al. Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain 2012;153(5): 1091-106
187. Vincenzi F, Targa M, Corciulo C, et al. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Pain 2013;154(6): 864-73
188. Han S, Thatte J, Buzard DJ, Jones RM. Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists. J Med Chem 2013;56(21): 8224-56
189. Murineddu G, Deligia F, Dore A, et al. Different classes of CB2 ligands potentially useful in the treatment of pain. Recent Pat CNS Drug Discov 2013;8(1): 42-69
190. Kusakabe K, Iso Y, Tada Y, et al. Selective CB2 agonists with anti-pruritic activity: Discovery of potent and orally available bicyclic 2-pyridones. Bioorg Med Chem 2013;21(11): 3154-63
191. Petrov RR, Knight L, Chen SR, et al. Mastering tricyclic ring systems for desirable functional cannabinoid activity. Eur J Med Chem 2013;69: 881-907
192. Hollinshead SP, Tidwell MW, Palmer J, et al. Selective cannabinoid receptor type 2 (CB2) agonists: Optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. J Med Chem 2013;56(14): 5722-33
193. Atwood BK, Straiker A, Mackie K. CB (2): Therapeutic target-in-waiting. Prog Neuro-psychopharmacol Biol Psychiatry 2012;38(1): 16-20
194. Landry RP, Martinez E, DeLeo JA, Romero-Sandoval EA. Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-Activated protein kinase phosphatases in a rat model of neuropathic pain. J Pain 2012;13(9): 836-48
195. Klauke AL, Racz I, Pradier B, et al. The cannabinoid CB receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol 2014;24(4): 608-20
196. Diaz P, Phatak SS, Xu J, et al. 6-Methoxy-N-Alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: Design, synthesis, and binding mode prediction. J Med Chem 2009;52(2): 433-44
197. Astruc-Diaz F, McDaniel SW, Xu JJ, et al. In vivo efficacy of enabling formulations based on hydroxypropylbeta-cyclodextrins, micellar preparation, and liposomes for the lipophilic cannabinoid CB2 agonist, MDA7. J Pharm Sci 2013;102(2): 352-64
198. Naguib M, Xu JJ, Diaz P, et al. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg 2012;114(5): 1104-20
199. Xu JJ, Diaz P, Bie B, et al. Spinal gene expression profiling and pathways analysis of a CB agonist (MDA7)-Targeted prevention of paclitaxel-induced neuropathy. Neuroscience 2014;28;260: 185-94
200. Cushing CC, Walters RW, Hoffman L. Aggregated N-of-1 randomized controlled trials: Modern data analytics applied to a clinically valid method of intervention effectiveness. J Pediatr Psychol 2014;39(2): 138-50
201. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: A pragmatic clinical decision methodology for patientcentered comparative effectiveness research. J Clin Epidemiol 2013;66(Suppl 8): S21-8
202. Vohra S, Punja S. N-of-1 trials: Individualized medication effectiveness tests. Virtual Mentor 2013;15(1): 42-5.